Top
Advanced Retinal Pigmentosa - Healing Genes
1360
post-template-default,single,single-post,postid-1360,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Advanced Retinal Pigmentosa

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa

Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)


Phase 1/2

DESCRIPTION:

Doctors at several eye research foundations are seeking patients with Advanced Retinal Pigmentosa. The drug uses a genetic editing tool, delivered only within the retina, designed to insert a gene for channelrhodopsin-2, to create new photosensors in retinal ganglion cells and potentially restore vision.

Treatment will involve a single injection surgery to the retina at the back of the eye, then follow up for 2 years.


PATIENT MUST:

  • Be 18 years of age and older
  • Meet genetic screening requirements specific to the study aim
  • Not have participated in a clinical study (ocular or non-ocular) with an investigational drug, agent or therapy in the past six months

THE STUDY INVOLVES:

  1. Screening before the treatment.
  2. A single injection of the genetic therapy to the retina at the back of the eye.
  3. Follow up for 2 years.

LOCATIONS AND CONTACTS:
The study locations include:
Duke Eye Center, Duke University Medical Center in Durham, NC. Map.
Cincinnati Eye Institute in Cincinnati, OH, Map.
University of California Dept. of Ophthalmology in San Francisco, CA. Map.
Retina Foundation of the Southwest in Dallas, TX. Map.

Contact:
Clinical Trials Registry Team  |  1-877-277-8566  |  [email protected]
 
SPONSOR INFORMATION:
Allergan
 
Or go online:
https://clinicaltrials.gov/ct2/show/NCT02556736

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader